Cardinal Health Unveils Game-Changing Report on the Thriving Cell and Gene Therapy Industry

Dublin, Ohio, May 7, 2025 /PRNewswire/ — Cardinal Health has released its first-ever 2025 Advanced Therapies Report, focusing on the future of cell and gene therapies (CGTs). This report sheds light on how these therapies could change patient care.

The report is based on feedback from over 100 healthcare providers, expert interviews, and a patient’s account of their experience with CAR T-cell therapy. Craig Cowman, EVP of Biopharma Solutions at Cardinal Health, notes that CGTs could greatly improve the lives of those with chronic diseases like cancer and diabetes. He emphasizes the promise these therapies hold for many patients.

Despite the exciting potential, the report reveals that significant challenges affect access and utilization of CGTs. In fact, it predicts that more than 200 therapies could be approved and over 100,000 U.S. patients may receive treatment by 2030.

Here are some key findings:

• Access Obstacles: Many still face hurdles. 56% of providers say high costs are a barrier, while 54% highlight inadequate reimbursement as an issue.
• Need for Collaboration: The report stresses the importance of collaboration among all stakeholders. 69% of providers believe innovative payment models could enhance access.
• Patient Support Gaps: 64% of providers noted that a lack of social support often prevents patients from receiving needed treatments. In addition, 57% cited prior authorization denials as a significant hurdle.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, suggests that the industry is still in its early stages but changing rapidly. She calls for thoughtful discussions on how to navigate these transformations and improve patient access.

CGTs hold a potential that mirrors past breakthroughs in medicine. For example, when antibiotics were first introduced, they revolutionized infection treatment. Today’s CGTs could similarly reshape how we approach chronic and genetic diseases.

According to recent statistics from a research study, the number of CGTs in clinical trials has surged over the last five years, reflecting growing investment in this area. The rise in trials aligns with increasing interest and funding in bioengineering and personalized medicine.

You can check out the full report here.

Cardinal Health is a leader in distribution and manufacturing of healthcare products, committed to innovative solutions that better the lives of the people they serve. You can learn more about their initiatives at cardinalhealth.com and in their Newsroom.

Source link

Cardinal Health